You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies

  • Technology appraisal guidance
  • Reference number: TA171
  • Published:  18 June 2009
  • Last updated:  26 June 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Response to consultee, commentator and public comments on the ACD and comments from website consultation

  • Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) issued October 2008

  • Response to consultee, commentator and public comments on the second Appraisal Consultation Document (ACD) issued January 2009

  • Letter from the Department of health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma

  • Letter from Celgene sent on 26th February 2009


This page was last updated: 30 March 2010

Back to top